Skip to main content

Table 4 Number of patients (and percentage of subgroup total) in the Safety and Efficacy (ITT and PP) analysis populations, grouped by treatment duration

From: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

 

Treatment duration (months)

 

Population

< 4

4

> 4

Total

Safety

3 (9.4%)

14 (43.8%)

15 (46.9%)

32

Intent-to-treat (ITT)

n.a.

14 (48.3%)

15 (51.7%)

29

Per-protocol (PP)

n.a.

14 (56.0%)

11 (44.0%)

25

  1. n.a. = not applicable as this analysis population, by definition, contained no patients treated for less than 4 months
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us